قالب وردپرس درنا توس
Home / Health / Interleukin 6 receptor antagonist in severely ill patients with Covid-19

Interleukin 6 receptor antagonist in severely ill patients with Covid-19



With the support of the European Union-through FP7-HEALTH-2013-INNOVATION: the platform of the European Preparedness (Re)epidemic Alliance (PREPARE) Consortium (602525); and the Horizon 2020 Research and Innovation Program: Europe Covid-19 Fast Europe Emergency Research Response (RECOVER) Consortium (101003589), as well as the Australian National Health and Medical Research Council (APP1101719), New Zealand Health Research Council (16/631), and Canadian Institutes of Health’s patient-oriented research and innovation clinical trial program grants (158584) ), British NIHR and NIHR Imperial Biomedical Research Center, Irish Health Research Council (CTN 201

4-012), UPMC “Learning by Doing” program, Breast Cancer Research Foundation, French Ministry of Health (PHRC-20-0147), Minderoo Foundation, Amgen, Eisai, Global Adaptive Research Alliance and Wellcome Trust Innovation Project (215522). Dr. Gordon was funded by the NIHR Research Professor Scholarship (RP-2015-06-18) and Dr. Shankar-Hari was funded by the NIHR Clinical Scientist Scholarship (CS-2016-16-011).

The disclosure form provided by the author is available on NEJM.org for the full text of this article.

The members of the writing committee are as follows: Anthony C. Gordon, MB, BS, MD, Paul R. Mouncey, M.Sc., Farah Al-Beidh, Ph.D., Kathryn M. Rowan, Ph.D., Alistair, MD D. Nichol, MD Yaseen M. Arabi, MD Djillali Annane, MD Abi Beane, MD Linda, MD Wilma van Bentum-Puijk R. Berry, MD, MD Zahra Bhimani, MPH, Marc JM Bonten MD, PhD, Charlotte Dr. A. Bradbury, MB, Ch.B. Ph.D., Dr. Frank M. Brunkhorst, Doctor of Medicine, Adrian Buzgau, Master of Science, Allen C. Cheng, Doctor of Medicine, Doctor of Science, Michelle Dr. Michelle A. Detry, Eamon J., MB, B. Ch., Ph.D., Mark Fitzgerald, Ph.D., Herman Goossens, Ph.D., Rashan Haniffa, Ph.D., Alisa M.Higgins, Ph.D., Thomas E. Hills (Hills), Dr. Christopher Howa (Christopher M., MD, Elizabeth Lorenz, MD, John C ·Marshall, MD, Florian B. Mayer, MD, MD, Daniel F. Macaulay, MD, Anna McCauley, MD, Shay McGuinness, MD, MD, Brian J. McVerry, MD, Stephanie K. Montgomery, MD, Susan C. Morpeth, MD, Srinivas Murthy, MD, Katrina Orr, MD, Rachael L. Parke, MD, Jane C. Parker, National Bank, Assad E. Patanwala (Dr. Adam EW Seymour, Dr. Manu Shankar-Hari, PhD, Dr. Wendy I. Sligl, Dr. Alexis F. Turgeon, Dr. Anne M. Turner, MPH, Frank L. Dr. van de Veerdonk. D., Ryan Zarychanski, MD, Cameron Green, M.Sc., Roger J. Lewis, MD, Ph.D., Derek C. Angus, MD, MPH, Colin J. McArthur, MD, Scott Berry, Ph.D. Steve A. Webb (Steve A. Webb) and Lennie PG Derde, MD.

The views expressed in this publication are those of the author, and not necessarily those of the National Health Service, the National Institute of Health (NIHR) or the Department of Health and Social Care.

This article was published on NEJM.org on February 25, 2021.

The data sharing statement provided by the author is available in the full text of this article on NEJM.org.

We are grateful to the staff of the NIHR Clinical Research Network (UK), UPMC Health System Health Services (US), and the Paris Public Research Center-Paris Advanced Research and Innovation Center, France. Thank them for their support in recruiting participants.


Source link